Hoth Therapeutics (NASDAQ:HOTH) Earns Buy Rating from D. Boral Capital
D. Boral Capital reaffirmed their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH – Free Report) in a research report sent to investors on Thursday,Benzinga reports. The firm currently has a $5.00 price objective on the stock. Separately, Wall Street Zen lowered shares of Hoth Therapeutics from a “hold” rating to a “sell” rating in […]
D. Boral Capital reaffirmed their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH – Free Report) in a research report sent to investors on Thursday,Benzinga reports. The firm currently has a $5.00 price objective on the stock. Separately, Wall Street Zen lowered shares of Hoth Therapeutics from a “hold” rating to a “sell” rating in […]
